Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG

Durvalumab

1500 mg i.v. Q4W

DRUG

Olaparib

300 mg BID orally

Trial Locations (1)

University Hospital Cologne, Cologne